Assessment and Management of Cardiotoxicity in Hematologic Malignancies

Table 1

Patients with high risk of cardiotoxicity.

---

(i) High-dose anthracycline (e.g., and )

(ii) High-dose radiotherapy (≥30 Gy) if the heart is in the treatment field

(iii) Lower-dose anthracycline (e.g., and ) or HER inhibitors or VEGF inhibitors or proteasome inhibitors of Bcr-Abl tyrosine kinase inhibitors and presence of any of the following factors:

 (a) years

 (b) Lower-dose radiotherapy (<30 Gy) where the heart is in the radiation field

 (c) ≥2 risk factors, including smoking, hypertension, diabetes mellitus, dyslipidemia, chronic renal insufficiency, and obesity

(iv) Previous heart disease

(v) Elevated cardiac biomarkers (pro-BNP, NT-pro-BNP, and troponin) before initiation of anticancer therapy

---